Aarey Drugs [AAREYDRUGS] vs Biofil Chemicals [BIOFILCHEM] Detailed Stock Comparison
Aarey Drugs
NSE
Loading...
Biofil Chemicals
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Aarey Drugs wins in 10 metrics, Biofil Chemicals wins in 7 metrics, with 0 ties. Aarey Drugs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Aarey Drugs | Biofil Chemicals | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 46.01 | 128.47 | Aarey Drugs |
| Price-to-Book Ratio | 11.17 | 3.87 | Biofil Chemicals |
| Debt-to-Equity Ratio | 25.17 | 2.51 | Biofil Chemicals |
| EV/EBITDA | 18.23 | 63.51 | Aarey Drugs |
| Profit Margin (TTM) | 0.93% | 1.67% | Biofil Chemicals |
| Operating Margin (TTM) | 2.67% | 3.13% | Biofil Chemicals |
| EBITDA Margin (TTM) | 2.67% | 3.13% | Biofil Chemicals |
| Return on Equity | 2.91% | 3.02% | Biofil Chemicals |
| Return on Assets (TTM) | 1.69% | 0.99% | Aarey Drugs |
| Free Cash Flow (TTM) | $44.49M | $-20.24M | Aarey Drugs |
| 1-Year Return | 9.02% | -37.25% | Aarey Drugs |
| Price-to-Sales Ratio (TTM) | 0.42 | 2.13 | Aarey Drugs |
| Enterprise Value | $2.20B | $732.03M | Aarey Drugs |
| EV/Revenue Ratio | 0.46 | 2.19 | Aarey Drugs |
| Gross Profit Margin (TTM) | -1.00% | 6.55% | Biofil Chemicals |
| Revenue per Share (TTM) | $160 | $20 | Aarey Drugs |
| Earnings per Share (Diluted) | $1.43 | $0.34 | Aarey Drugs |
| Beta (Stock Volatility) | N/A | 0.97 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Aarey Drugs vs Biofil Chemicals Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Aarey Drugs | -0.49% | -0.62% | -0.79% | 15.87% | 61.96% | 13.84% |
| Biofil Chemicals | -2.40% | -1.52% | -6.66% | -8.13% | -10.89% | -29.49% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Aarey Drugs | 9.02% | 72.54% | 51.05% | 51.05% | 51.05% | 51.05% |
| Biofil Chemicals | -37.25% | -18.95% | 18.91% | 85.75% | 85.75% | 85.75% |
Performance & Financial Health Analysis: Aarey Drugs vs Biofil Chemicals
| Metric | AAREYDRUGS | BIOFILCHEM |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.87B | ₹710.84M |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 35,260 | 7,614 |
| 90 Day Avg. Volume | 38,089 | 6,911 |
| Last Close | ₹65.48 | ₹42.63 |
| 52 Week Range | ₹32.85 - ₹74.80 | ₹40.40 - ₹91.87 |
| % from 52W High | -12.46% | -53.60% |
| All-Time High | ₹74.80 (Sep 02, 2024) | ₹356.10 (Dec 14, 2020) |
| % from All-Time High | -12.46% | -88.03% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.18% | -0.46% |
| Quarterly Earnings Growth | 0.11% | -0.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.01% | 0.02% |
| Operating Margin (TTM) | 0.03% | 0.03% |
| Return on Equity (TTM) | 0.03% | 0.03% |
| Debt to Equity (MRQ) | 25.17 | 2.51 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹5.89 | ₹11.29 |
| Cash per Share (MRQ) | N/A | ₹0.15 |
| Operating Cash Flow (TTM) | ₹843.50M | ₹-19,236,000 |
| Levered Free Cash Flow (TTM) | ₹40.24M | ₹-21,437,750 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Aarey Drugs vs Biofil Chemicals
| Metric | AAREYDRUGS | BIOFILCHEM |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 46.01 | 128.47 |
| Forward P/E | N/A | N/A |
| PEG Ratio | N/A | N/A |
| Price to Sales (TTM) | 0.42 | 2.13 |
| Price to Book (MRQ) | 11.17 | 3.87 |
| Market Capitalization | ||
| Market Capitalization | ₹1.87B | ₹710.84M |
| Enterprise Value | ₹2.20B | ₹732.03M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.46 | 2.19 |
| Enterprise to EBITDA | 18.23 | 63.51 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.97 |
| Book Value per Share (MRQ) | ₹5.89 | ₹11.29 |
Financial Statements Comparison: Aarey Drugs vs Biofil Chemicals
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AAREYDRUGS | BIOFILCHEM |
|---|---|---|
| Revenue/Sales | ₹1.08B | ₹83.51M |
| Cost of Goods Sold | ₹1.09B | ₹78.04M |
| Gross Profit | ₹-10.77M | ₹5.47M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-52.60M | ₹247,000 |
| EBITDA | ₹26.86M | ₹3.45M |
| Pre-Tax Income | ₹16.25M | ₹2.54M |
| Income Tax | ₹11.55M | ₹541,000 |
| Net Income (Profit) | ₹4.70M | ₹2.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AAREYDRUGS | BIOFILCHEM |
|---|---|---|
| Cash & Equivalents | ₹14.73M | ₹1.33M |
| Total Current Assets | ₹2.13B | ₹425.54M |
| Total Current Liabilities | ₹968.80M | ₹318.48M |
| Long-Term Debt | ₹19.87M | N/A |
| Total Shareholders Equity | ₹1.38B | ₹187.82M |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AAREYDRUGS | BIOFILCHEM |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | AAREYDRUGS | BIOFILCHEM |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 35,260 | 7,614 |
| Average Daily Volume (90 Day) | 38,089 | 6,911 |
| Shares Outstanding | 27.95M | 16.27M |
| Float Shares | 13.14M | 7.50M |
| % Held by Insiders | 0.53% | 0.62% |
| % Held by Institutions | 0.02% | 0.00% |
Dividend Analysis & Yield Comparison: Aarey Drugs vs Biofil Chemicals
| Metric | AAREYDRUGS | BIOFILCHEM |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |